Last reviewed · How we verify
Fluarix Quadrivalent® Comparator Vaccine
Fluarix Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
Fluarix Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Fluarix Quadrivalent® Comparator Vaccine |
|---|---|
| Sponsor | Medicago |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing two influenza A strains and two influenza B strains. Upon administration, these viral antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that provide protection against infection with matching circulating influenza strains.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (PHASE2)
- Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly (PHASE3)
- Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression (PHASE4)
- Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix Quadrivalent® Comparator Vaccine CI brief — competitive landscape report
- Fluarix Quadrivalent® Comparator Vaccine updates RSS · CI watch RSS
- Medicago portfolio CI